title: Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy.
abstract: BACKGROUND
  Posttransplantation lymphoproliferative disorders after solid organ transplantation are a serious complication occurring in 1-10% of patients. Different therapies have been used, but the optimal treatment is unknown. There is relatively little information in the literature on the experience with cytotoxic chemotherapy.
  
  
  METHODS
  The disease stage of patients with biopsy-documented posttransplantation lymphoproliferative was determined with standard methods to establish the extent of the disease. Patients in whom the disease failed to regress after initial management, which included reduction in immunosuppression, were treated with a combination chemotherapy regimen consisting of six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Response to therapy was determined by following previously defined sites of disease with appropriate tests. Patients were maintained on a reduced dose of immunosuppressants.
  
  
  RESULTS
  In the four patients studied, lymphoproliferative disorders developed after heart (three cases) or lung (one case) transplantation, which did not regress after immunosuppression was reduced. All four experienced a complete remission with CHOP chemotherapy, which continued at 3, 13+, 20 and 30+ months after completion of treatment. One patient died of sepsis after completing therapy at a point when his leukocyte count was normal, and no evidence of posttransplantation lymphoproliferative disorder was found at autopsy. A second patient died of liver failure with no clinical evidence of lymphoproliferative disorder.
  
  
  CONCLUSIONS
  Although this is a small series, it demonstrates that patients with posttransplantation lymphoproliferative disorders may respond to cytotoxic chemotherapy. The duration of response is undetermined.
authors.affiliation: Department of Medicine, Columbia-Presbyterian Medical Center, New York, New York 10032.
authors.forename: T J
authors.initials: TJ
authors.lastname: Garrett
authors.forename: A
authors.initials: A
authors.lastname: Chadburn
authors.forename: M L
authors.initials: ML
authors.lastname: Barr
authors.forename: R E
authors.initials: RE
authors.lastname: Drusin
authors.forename: J M
authors.initials: JM
authors.lastname: Chen
authors.forename: L L
authors.initials: LL
authors.lastname: Schulman
authors.forename: C R
authors.initials: CR
authors.lastname: Smith
authors.forename: D S
authors.initials: DS
authors.lastname: Reison
authors.forename: E A
authors.initials: EA
authors.lastname: Rose
authors.forename: R E
authors.initials: RE
authors.lastname: Michler
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D016130:Immunophenotyping; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000209:etiology; D016400:Lymphoma, Large-Cell, Immunoblastic / Q000188:drug therapy / Q000209:etiology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000209:etiology; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000209:etiology* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects*; D011239:Prednisolone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone